Quantum Genomics Quantum Genomics
  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
  • Science
    • The BAPAIs
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Shareholder letter
    • General meetings
    • Shareholding
    • Financial calendar
    • Contacts
  • Contact us
  • Français
News

First patient enrolled in REFREH study

Quantum on 8 July 2021

First patient enrolled in REFREH study

Read the press realease 

Previous Post (p) August 28th: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure
Next Post (n) Testimony of Denis, shareholder since 2016 (in French)
Quantum 2021-07-08T08:20:30+02:00
About

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Contact us

33 rue Marbeuf
75008 Paris

[email protected]
+33(0)1 85 34 77 70

Write us

Quick access
  • Strategy
  • Pipeline
  • Did you know that ?
  • Scientific Publications
Search

 

© 2019 Quantum Genomics - Legal notice - Website terms and conditions

  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
  • Science
    • The BAPAIs
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Shareholder letter
    • General meetings
    • Shareholding
    • Financial calendar
    • Contacts
  • Contact us
  • Français
  • Blog
  • Home
  • Contact us